open access

Vol 13, No 2 (2010)
Original articles
Published online: 2011-05-20
Submitted: 2012-01-23
Get Citation

Role of F-18-FDG-PET/CT in restaging of patients affected by gastrointestinal stromal tumours (GIST)

Francesco Bertagna, Giovanni Bosio, Emanuela Orlando, Giorgio Biasiotto, Raffaele Giubbini
Nucl. Med. Rev 2010;13(2):76-80.

open access

Vol 13, No 2 (2010)
Original articles
Published online: 2011-05-20
Submitted: 2012-01-23

Abstract

BACKGROUND: Gastrointestinal stromal tumours (GISTs) are a subset of mesenchymal tumours that represent the most common mesenchymal neoplasms of the gastrointestinal (GI) tract and account for less than 1% of all gastrointestinal tumours.
MATERIAL AND METHODS: We retrospectively evaluated 19 patients (6 females and 13 males; median age: 61 years ± 15 standard deviation) affected by GIST histologically documented after surgical intervention or biopsy.
RESULTS: F18-FDG-PET/CT had identified pathologic uptakes and was considered positive for neoplastic tissue in 10 patients (53%) and negative in 9 (47%), in concordance with radiological findings.
CONCLUSIONS: F18-FDG-PET/CT is a feasible, reliable, and accurate method to restage patients affected by previously histologically confirmed GIST, also in the absence of a staging study.
Nuclear Med Rev 2010; 13, 2: 76–80

Abstract

BACKGROUND: Gastrointestinal stromal tumours (GISTs) are a subset of mesenchymal tumours that represent the most common mesenchymal neoplasms of the gastrointestinal (GI) tract and account for less than 1% of all gastrointestinal tumours.
MATERIAL AND METHODS: We retrospectively evaluated 19 patients (6 females and 13 males; median age: 61 years ± 15 standard deviation) affected by GIST histologically documented after surgical intervention or biopsy.
RESULTS: F18-FDG-PET/CT had identified pathologic uptakes and was considered positive for neoplastic tissue in 10 patients (53%) and negative in 9 (47%), in concordance with radiological findings.
CONCLUSIONS: F18-FDG-PET/CT is a feasible, reliable, and accurate method to restage patients affected by previously histologically confirmed GIST, also in the absence of a staging study.
Nuclear Med Rev 2010; 13, 2: 76–80
Get Citation

Keywords

positron emission tomography; PET; gastrointestinal stromal tumours; GIST; imatinib mesylate

About this article
Title

Role of F-18-FDG-PET/CT in restaging of patients affected by gastrointestinal stromal tumours (GIST)

Journal

Nuclear Medicine Review

Issue

Vol 13, No 2 (2010)

Pages

76-80

Published online

2011-05-20

Bibliographic record

Nucl. Med. Rev 2010;13(2):76-80.

Keywords

positron emission tomography
PET
gastrointestinal stromal tumours
GIST
imatinib mesylate

Authors

Francesco Bertagna
Giovanni Bosio
Emanuela Orlando
Giorgio Biasiotto
Raffaele Giubbini

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl